Cargando…

Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?

Pharmacotherapy provides an adjunct to behaviour modification in the management of obesity. There are a number of new drug therapies purportedly targeting appetite; liraglutide, and bupropion/naltrexone, which are European Medicines Agency and US Food and Drug Administration (FDA) approved, and lorc...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Carl A., Christiansen, Paul, Halford, Jason C. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504125/
https://www.ncbi.nlm.nih.gov/pubmed/28421338
http://dx.doi.org/10.1007/s00592-017-0994-x
_version_ 1783249221079531520
author Roberts, Carl A.
Christiansen, Paul
Halford, Jason C. G.
author_facet Roberts, Carl A.
Christiansen, Paul
Halford, Jason C. G.
author_sort Roberts, Carl A.
collection PubMed
description Pharmacotherapy provides an adjunct to behaviour modification in the management of obesity. There are a number of new drug therapies purportedly targeting appetite; liraglutide, and bupropion/naltrexone, which are European Medicines Agency and US Food and Drug Administration (FDA) approved, and lorcaserin and phentermine/topiramate, which have FDA approval only. Each of the six drugs, used singly or in combination, has distinct pharmacological, and presumably distinct behavioural, mechanisms of action, thus the potential to provide defined therapeutic options to personalise the management of obesity. Yet, with regard to pharmacotherapy for obesity, we are far from true personalised medicine. We review the limited mechanistic data with four mono and combination pharmacotherapies, to assess the potential for tailoring their use to target specific obesogenic behaviours. Potential treatment options are considered, but in the absence of adequate research in respect to effects of these drugs on eating behaviour, neural activity and psychological substrates that underlie poorly controlled eating, we are far from definitive therapeutic recommendations. Specific mechanistic studies and broader behavioural phenotyping, possibly in conjunction with pharmacogenetic research, are required to characterise responders for distinct pharmacotherapeutic options.
format Online
Article
Text
id pubmed-5504125
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-55041252017-07-25 Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? Roberts, Carl A. Christiansen, Paul Halford, Jason C. G. Acta Diabetol Review Article Pharmacotherapy provides an adjunct to behaviour modification in the management of obesity. There are a number of new drug therapies purportedly targeting appetite; liraglutide, and bupropion/naltrexone, which are European Medicines Agency and US Food and Drug Administration (FDA) approved, and lorcaserin and phentermine/topiramate, which have FDA approval only. Each of the six drugs, used singly or in combination, has distinct pharmacological, and presumably distinct behavioural, mechanisms of action, thus the potential to provide defined therapeutic options to personalise the management of obesity. Yet, with regard to pharmacotherapy for obesity, we are far from true personalised medicine. We review the limited mechanistic data with four mono and combination pharmacotherapies, to assess the potential for tailoring their use to target specific obesogenic behaviours. Potential treatment options are considered, but in the absence of adequate research in respect to effects of these drugs on eating behaviour, neural activity and psychological substrates that underlie poorly controlled eating, we are far from definitive therapeutic recommendations. Specific mechanistic studies and broader behavioural phenotyping, possibly in conjunction with pharmacogenetic research, are required to characterise responders for distinct pharmacotherapeutic options. Springer Milan 2017-04-19 2017 /pmc/articles/PMC5504125/ /pubmed/28421338 http://dx.doi.org/10.1007/s00592-017-0994-x Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Roberts, Carl A.
Christiansen, Paul
Halford, Jason C. G.
Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
title Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
title_full Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
title_fullStr Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
title_full_unstemmed Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
title_short Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
title_sort tailoring pharmacotherapy to specific eating behaviours in obesity: can recommendations for personalised therapy be made from the current data?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504125/
https://www.ncbi.nlm.nih.gov/pubmed/28421338
http://dx.doi.org/10.1007/s00592-017-0994-x
work_keys_str_mv AT robertscarla tailoringpharmacotherapytospecificeatingbehavioursinobesitycanrecommendationsforpersonalisedtherapybemadefromthecurrentdata
AT christiansenpaul tailoringpharmacotherapytospecificeatingbehavioursinobesitycanrecommendationsforpersonalisedtherapybemadefromthecurrentdata
AT halfordjasoncg tailoringpharmacotherapytospecificeatingbehavioursinobesitycanrecommendationsforpersonalisedtherapybemadefromthecurrentdata